Accessibility Statement Skip Navigation
  • Resources
  • Data Privacy
  • Contact Us
  • Send a Release
Return to PR Newswire homepage
  • News
  • Products
  • Contact
Search
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News Releases view all

    • News in Focus
        • Browse News Releases

        • All News Releases
        • All Public Company
        • All Multimedia

        • All Multimedia
        • All Photos
        • All Videos
    • Business & Money
        • Auto & Transportation

        • Aerospace & Defense
        • Air Freight
        • Airlines & Aviation
        • Automotive
        • Maritime & Shipbuilding
        • Railroads & Intermodal Transportation
        • Supply Chain/Logistics
        • Transportation, Trucking & Railroad
        • Travel
        • Trucking & Road Transportation
        • View All Auto & Transportation

        • Business Technology

        • Blockchain
        • Broadcast Tech
        • Computer & Electronics
        • Computer Accessories
        • Computer Hardware
        • Computer Networks
        • Computer Software
        • Data Analytics
        • Electronic Commerce
        • Electronic Components
        • Electronic Design Automation
        • Financial Technology
        • High-Tech Security
        • Internet Technology
        • Nanotechnology
        • Semiconductors
        • View All Business Technology

        • Entertain­ment & Media

        • Advertising
        • Art, Culture & Design
        • Books
        • Entertainment
        • Film & Motion Picture
        • Magazines
        • Music
        • Publishing & Information Services
        • Radio & Podcast
        • Television
        • View All Entertain­ment & Media

        • Financial Services & Investing

        • Accounting News & Issues
        • Acquisitions, Mergers & Takeovers
        • Banking & Financial Services
        • Bankruptcy
        • Bond & Stock Ratings
        • Conference Call Announcements
        • Contracts
        • Cryptocurrency
        • Dividends
        • Earnings
        • Earnings Projections or Forecasts
        • Financing Agreements
        • Insurance
        • Joint Ventures
        • Mutual Funds
        • Offerings
        • Private Placement
        • Real Estate
        • Restructuring & Recapitalization
        • Sales Reports
        • Shareholder Activism
        • Shareholder Meetings
        • Venture Capital
        • View All Financial Services & Investing

        • General Business

        • Awards
        • Commercial Real Estate
        • Corporate Expansion
        • Earnings
        • Environmental, Social and Governance (ESG)
        • Human Resource & Workforce Management
        • Licensing/marketing agreements
        • New Products & Services
        • Obituary
        • Outsourcing Businesses
        • Overseas Real Estate (Non-US)
        • Personnel Announcements
        • Residential Real Estate
        • Small-Business Services
        • Socially Responsible Investing
        • Surveys, Polls & Research
        • Trade Show News
        • View All General Business

    • Science & Tech
        • Consumer Technology

        • Artificial Intelligence
        • Blockchain
        • Cloud Computing/Internet of Things
        • Computer Accessories
        • Computer Electronics
        • Computer Hardware
        • Computer Networks
        • Computer Software
        • Consumer Electronics
        • Cryptocurrency
        • Data Analytics
        • Electronic Commerce
        • Electronic Design Automation
        • Financial Technology
        • Mobile Devices/Apps
        • Social Media
        • STEM (Science, Tech, Engineering, Math)
        • Wireless Communications
        • View All Consumer Technology

        • Energy & Natural Resources

        • Alternative Energies
        • Chemical
        • Electrical Utilities
        • General Manufacturing
        • Mining
        • Mining & Metals
        • Natural Gas Utilities
        • Oil & Energy
        • Oil & Gas Discoveries
        • Utilities
        • Water Utilities
        • View All Energy & Natural Resources

        • Environ­ment

        • Conservation & Recycling
        • Environmental Issues
        • Environmental Policy
        • Environmental Products & Services
        • Green Technology
        • Natural Disasters
        • View All Environ­ment

        • Heavy Industry & Manufacturing

        • Aerospace & Defense
        • Agriculture
        • Chemical
        • Construction & Building
        • General Manufacturing
        • HVAC (Heating, Ventilation & Air-Conditioning)
        • Machinery
        • Machine Tools, Metalworking & Metallurgy
        • Mining
        • Mining & Metals
        • Paper, Forest Products & Containers
        • Precious Metals
        • Textiles
        • Tobacco
        • View All Heavy Industry & Manufacturing

        • Telecomm­unications

        • Computer Accessories
        • Computer Networks
        • Mobile Devices/Apps
        • Telecommunications
        • Telecommunications Carriers & Services
        • Telecommunications Equipment
        • VoIP (Voice over Internet Protocol)
        • Wireless Communications
        • View All Telecomm­unications

    • Lifestyle & Health
        • Consumer Products & Retail

        • Animals & Pets
        • Beers, Wine & Spirits
        • Beverages
        • Cannabis
        • Cosmetics and Personal Care
        • Fashion
        • Food
        • Furniture & Furnishings
        • Home Improvement
        • Household, Consumer & Cosmetics
        • Household Products
        • Jewelry
        • Non-Alcoholic Beverages
        • Office Products
        • Product Recalls
        • Restaurants
        • Retail
        • Supermarkets
        • Toys
        • View All Consumer Products & Retail

        • Entertain­ment & Media

        • Advertising
        • Art, Culture & Design
        • Books
        • Entertainment
        • Film & Motion Picture
        • Magazines
        • Music
        • Publishing & Information Services
        • Radio & Podcast
        • Television
        • View All Entertain­ment & Media

        • Health

        • Biometrics
        • Biotechnology
        • Clinical Trials & Medical Discoveries
        • Dentistry
        • FDA Approval
        • Fitness/Wellness
        • Health Care & Hospitals
        • Health Insurance
        • Infectious Disease Control
        • International Medical Approval
        • Medical Equipment
        • Medical Pharmaceuticals
        • Mental Health
        • Pharmaceuticals
        • Supplementary Medicine
        • View All Health

        • Sports

        • Outdoors, Camping & Hiking
        • Sporting Events
        • Sports
        • Sports Equipment & Accessories
        • View All Sports

        • Travel

        • Amusement Parks & Tourist Attractions
        • Gambling & Casinos
        • Hotels & Resorts
        • Outdoors, Camping & Hiking
        • Passenger Aviation
        • Travel
        • View All Travel

    • Policy & Public Interest
        • Policy & Public Interest

        • Animal Welfare
        • Corporate Social Responsibility
        • Economic News, Trends & Analysis
        • Education
        • Environmental Products & Services
        • European Government
        • Natural Disasters
        • Not-for-Profit
        • Public Safety
        • View All Policy & Public Interest

    • People & Culture
        • People & Culture

        • Children-related news
        • Disabled Persons
        • Diversity, Equity & Inclusion
        • Hispanic-oriented news
        • LGBTQ+
        • Religion
        • Senior Citizens
        • Veterans
        • Women-Related news
        • View All People & Culture

    • Explore Our Platform
    • Plan Campaigns
    • Create with AI
    • Distribute Press Releases
    • Report Results
    • Amplify Content
    • All Products
    • General Inquiries
    • Request a Demo
    • Partnerships
    • Media Inquiries
    • Hamburger menu
    • PR Newswire: news distribution, targeting and monitoring Home
    • Send a Release
      • ALL CONTACT INFO
      • Contact Us


    • Searching for your content...

      No results found. Please change your search terms and try again.

      News Releases

      view all
      Close menu
    • News
    • Products
    • Contact
      • News Releases
      • Send a Release
      • Data Privacy
      • 2 News in Focus
      • 5 Business & Money
      • 5 Science & Tech
      • 5 Lifestyle & Health
      • 1 Policy & Public Interest
      • 1 People & Culture
      • News Releases
      • Send a Release
      • Data Privacy
      • Explore Our Platform
      • Plan Campaigns
      • Create with AI
      • Distribute Press Releases
      • Report Results
      • Amplify Content
      • All Products
      • News Releases
      • Send a Release
      • Data Privacy
      • General Inquiries
      • Request a Demo
      • Partnerships
      • Media Inquiries
      • Editorial Bureaus
      • News Releases
      • Send a Release
      • Data Privacy
      Close submenu (News in Focus) News in Focus
      • Browse News Releases
      • All Multimedia
      Close submenu (Business & Money) Business & Money
      • Auto & Transportation
      • Business Technology
      • Entertain­ment & Media
      • Financial Services & Investing
      • General Business
      Close submenu (Science & Tech) Science & Tech
      • Consumer Technology
      • Energy & Natural Resources
      • Environ­ment
      • Heavy Industry & Manufacturing
      • Telecomm­unications
      Close submenu (Lifestyle & Health) Lifestyle & Health
      • Consumer Products & Retail
      • Entertain­ment & Media
      • Health
      • Sports
      • Travel
      Close submenu (Policy & Public Interest) Policy & Public Interest
      • Policy & Public Interest
      Close submenu (People & Culture) People & Culture
      • People & Culture

      Ascletis Highlights Oral and Long-Acting Injectable Anti-Obesity Preclinical Studies at ObesityWeek® 2026

      • USA - English
      • APAC - Traditional Chinese
      Ascletis Pharma Inc.

      News provided by

      Ascletis Pharma Inc.

      16 Nov, 2026, 17:10 CST

      Share this article

      Share this article


      - ASC30_48 FDC, a first-in-class once-daily oral dual fixed-dose combination targeting GLP-1R and GIPR, achieved approximately 52% relative improvement in weight loss compared to ASC30 alone

      - ASC37, a GLP-1R/GIPR/GCGR triple peptide agonist designed for once-monthly to once-quarterly subcutaneous administration, demonstrates long-acting potential and robust weight loss

      HONG KONG, Nov. 16, 2026 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX: 1672, "Ascletis") recently presented key preclinical results for its oral small molecule GIPR agonist ASC48, GLP-1R/GIPR dual-targeted oral small molecule ASC30_48 FDC (a fixed-dose combination of ASC30 and ASC48), and a long-acting injectable GLP-1R/GIPR/GCGR triple peptide agonist ASC37 at ObesityWeek® 2026, being held November 14 to 17, 2026, in Washington, DC.

      The two poster presentations feature in vitro activity and oral pharmacokinetics (PK) of ASC48; weight-loss data for ASC30_48 FDC; and extended PK, in vitro insulin secretion activity and weight-loss activity of ASC37.

      Summary and Outlook

      ASC30_48 FDC is an in-house developed oral small molecule combination targeting GLP-1R and GIPR, with the potential to become a first-in-class one-pill, once-daily oral treatment for obesity and other metabolic diseases. These preclinical findings across receptor activity, oral pharmacokinetics and body weight reduction support advancing this program into further clinical development.

      ASC37 was developed using Ascletis' proprietary Artificial Intelligence-Assisted Structure-Based Drug Discovery (AISBDD) and Ultra-Long-Acting Platform (ULAP) technologies. By combining agonist activity at GLP-1R, GIPR and GCGR with a long-acting PK profile, ASC37 is designed to offer a potential once-monthly to once-quarterly subcutaneous treatment for chronic weight management, with an injection volume of no more than 1 mL. Preliminary preclinical data demonstrate promising efficacy on body weight reduction and appetite suppression, alongside favorable PK properties, supporting ASC37's potential as a best-in-class therapeutic candidate. Its PK, safety and efficacy will be further evaluated through clinical trials.

      Study Results for ASC48 and ASC30_48 FDC

      1. Greater Weight Reduction Observed with ASC30_48 FDC than with ASC30 Monotherapy in NHPs

      In a randomized study, 15 male cynomolgus monkeys were allocated to three groups following a 14-day acclimation period, with five animals per group. Animals received once-daily oral gavage for eight consecutive days: ASC30 (at 2 mg/kg), ASC48 (at 5 mg/kg), or ASC30_48 FDC (containing ASC30 at 2 mg/kg and ASC48 at 5 mg/kg). Body weight measurement was performed at a fixed time point each day throughout the study.

      On Day 9, body weight decreased by 10.5% with ASC30_48 FDC, compared with 6.9% with ASC30 monotherapy and 1.7% with ASC48 monotherapy. The combination therefore achieved approximately 52% greater relative body weight reduction compared to ASC30 monotherapy, corresponding to the proportion of weight loss increased by an additional 3.6%. These results support further evaluation of the combined GLP-1R/GIPR approach for weight management.

      2. Potent and Selective GIPR Agonist Activity of ASC48 in vitro

      In an in vitro human GIPR-mediated cAMP activation assay, ASC48 achieved an EC50 of 1 pM, compared with 3 pM for tirzepatide, demonstrating potent GIPR agonist activity of ASC48 in this assay. ASC48 showed no activity for human GLP-1R (IC50 > 10μM) or human GCGR (IC50 > 10μM) under the tested conditions, supporting its selective activity for human GIPR.

      3. Oral Pharmacokinetic Profile Supporting Once-Daily Development

      Following eight repeated oral gavage doses of ASC48 at 5 mg/kg in cynomolgus monkeys, the reported half-life was 16.2 hours and the area under the plasma concentration-time curve over 24 hours (AUC0–24h) was 14,500 h*ng/mL. These findings demonstrate robust oral bioavailability and drug exposure of ASC48 in non-human primates (NHPs) after oral dosing and, together with the once-daily efficacy study, support further evaluation of a once-daily oral regimen in humans.

      Study Results for ASC37

      1. Extended PK Profile Supporting the Potential for Once-Monthly to Once-Quarterly Dosing

      In an NHP study, ASC37 in a Self-Assembly Lipid Depot formulation and retatrutide in an aqueous formulation were each administered subcutaneously at 0.5 mg/kg, with three animals per group. The observed half-life of ASC37 was 372 hours (15.5 days), compared with 57.8 hours (approximately 2.4 days) for retatrutide, approximately 6.4 times as long. These results support the potential of ASC37 for once-monthly to once-quarterly subcutaneous administration in humans.

      2. Potent Insulin Secretion Activity in vitro

      In an in vitro insulin secretion assay using INS-1 832/3 cells, ASC37 achieved an EC50 of 0.9858 nM, compared with 23.03 nM for retatrutide, representing approximately 23.4-fold higher potency in this assay. The corresponding Emax values were 106.75% and 108.84%, respectively. These findings demonstrate potent insulin secretion activity of ASC37 in vitro, confirming its value for further clinical development.

      3. Robust Dose-Dependent Weight Loss in DIO Mice

      In a diet-induced obese (DIO) mouse model, ASC37 was administered subcutaneously once daily at doses of 1, 10 and 30 nmol/kg. On Day 12, body weight of the three groups decreased from Day 1 baseline by 14.1%, 30.1% and 41.5%, respectively, compared with a 4.7% decrease in the DIO vehicle group. Cumulative food intake also decreased in a dose-dependent manner. These results demonstrate weight-loss activity associated with appetite suppression of ASC37 in this preclinical model.

      About Ascletis Pharma Inc.

      Ascletis Pharma Inc. (1672.HK) is a fully integrated biotechnology company focused on discovering, developing and commercializing potentially first-in-class and best-in-class therapeutics for metabolic diseases, including obesity and diabetes. Leveraging its proprietary Artificial Intelligence-Assisted Structure-Based Drug Discovery (AISBDD), Ultra-Long-Acting Platform (ULAP) and Peptide Oral Transport ENhancement Technology (POTENT), Ascletis has built a wholly in-house pipeline of oral small molecules and peptides targeting GLP-1R, GIPR, GCGR and amylin pathways. Ascletis is advancing a robust pipeline of 15 differentiated assets leveraged from six new molecular entities (three small molecules and three peptides), which are being developed both as monotherapies and in combination. Its lead program, ASC30, a once-daily oral small molecule GLP-1R agonist, is being evaluated in two global Phase III studies in obesity. The Company's pipeline also includes oral small molecule dual and triple agonist fixed-dose combinations, a selective amylin receptor agonist, injectable peptide agonists and combinations spanning dual to quadruple agonism designed for once-monthly to once-quarterly subcutaneous dosing, and oral peptide agonists and combinations designed for once-weekly dosing.

      For more information, please visit www.ascletis.com.

      Contact:
      Peter Vozzo
      ICR Healthcare
      443-231-0505 (U.S.)
      [email protected]

      Ascletis Pharma Inc. PR and IR Teams
      +86-181-0650-9129 (China)
      [email protected]
      [email protected]

      SOURCE Ascletis Pharma Inc.

      Modal title

      Also from this source

      Ascletis Submits IND Application to the U.S. FDA for ASC30_39 FDC, a Potentially First-in-Class Oral Small Molecule Fixed-Dose Combination of GLP-1R Agonist and Selective Amylin Receptor Agonist, for the Treatment of Obesity

      Ascletis Submits IND Application to the U.S. FDA for ASC30_39 FDC, a Potentially First-in-Class Oral Small Molecule Fixed-Dose Combination of GLP-1R Agonist and Selective Amylin Receptor Agonist, for the Treatment of Obesity

      Ascletis Pharma Inc. (HKEX: 1672, "Ascletis") announces today the submission of an Investigational New Drug (IND) application to the U.S. Food and...

      Ascletis to Present Study Results of Oral Small Molecule GIPR Agonist ASC48 and GLP-1R/GIPR/GCGR Triple Peptide Agonist ASC37 at ObesityWeek® 2026

      Ascletis to Present Study Results of Oral Small Molecule GIPR Agonist ASC48 and GLP-1R/GIPR/GCGR Triple Peptide Agonist ASC37 at ObesityWeek® 2026

      Ascletis Pharma Inc. (HKEX: 1672, "Ascletis") announces two poster presentations of its obesity assets, oral small molecule GIPR agonist ASC48 and...

      More Releases From This Source

      Explore

      Pharmaceuticals

      Pharmaceuticals

      Biotechnology

      Biotechnology

      Health Care & Hospitals

      Health Care & Hospitals

      Fitness/Wellness

      Fitness/Wellness

      News Releases in Similar Topics

      Contact PR Newswire

      • General Inquiries
      • Request a Demo
      • Partnerships
      • Media Inquiries

      Products

      • Explore Our Platform
      • Plan Campaigns
      • Create with AI
      • Distribute Press Releases
      • Report Results
      • Amplify Content

      About

      • About PR Newswire
      • About Cision
      • Become a Publishing Partner
      • Careers
      • Accessibility Statement
      • APAC – Simplified Chinese
      • APAC
      • APAC - Traditional Chinese
      • Arabic
      • Brazil
      • Canada
      • Czech
      • Denmark
      • Finland
      • France
      • Germany
      • India
      • Indonesia
      • Israel
      • Italy
      • Japan
      • Korea
      • Mexico
      • Middle East
      • Netherlands
      • Norway
      • Poland
      • Portugal
      • Russia
      • Slovakia
      • Spain
      • Sweden
      • United Kingdom
      • United States
      • Vietnam

      My Services

      • All New Releases
      • Platform

      Do not sell or share my personal information:

      • Submit via [email protected] 
      • Call Privacy toll-free: 877-297-8921

      Contact Cision

      Products

      About

      My Services
      • All News Releases
      • Platform
      [email protected]
      • Terms of Use
      • Privacy Policy
      • Information Security Policy
      • Site Map
      • RSS
      • Cookie Settings
      • Accessibility
      Copyright © 2026 Cision US Inc.